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The mechanism leading to hyperlipidemia in the nephrotic syndrome is not fully 
understood but may be related in part to loss of high density lipoproteins in the 
urine of patients with nephrosis. To prove this hypothesis, we compared serum 
lipoprotein profiles with the excretion of high density lipoproteins in urine in 19 
nephrotic patients. Serum cholesterol ranged from 19-152 (median value 45) mg/dl 
in very low density lipoproteins (VLDL), from 130-443 (median 186) mg/dl in low 
density lipoproteins (LDL) and from 19-64 (median 33) mg/dl in high density 
lipoproteins (HDL). Hyperlipoproteinemia was found in 17 patients, which was 
classified as phenotype IIa (Fredrickson) in 2, as phenotype IIb in 9 and as 
phenotype IV in 6 subjects. Two patients showed normal lipoprotein patterns. 
VLDL- and LDL-cholesterol were not found in detectable amounts in urine, 
whereas HDL-cholesterol was measured in low concentrations from 0.1-8.3 mg/24 
h in all samples. There was no correlation between serum HDL-cholesterol and 
urinary HDL-cholesterol, but a positive correlation between serum LDL-cholesterol 
and urinary HDL-cholesterol (r = + 0.54, p < 0.05). However, the total amount of 
the daily urinary loss of HDL (< 1% of total plasma HDL) seems not to be 
sufficient to explain hyperlipoproteinemia in the nephrotic syndrome. 
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The mechanisms causing hyperlipidemia in the nephrotic syndrome are complex 
and include both altered catabolism and enhanced synthesis of lipids [l-6]. In these 
patients an elevated excretion of urinary lipids has long been recognized [7,8] and it 
was suggested that loss of high density lipoproteins in urine might be related to 
h~er~poproteine~a in serum [9,10]. 
Although HDL was identified in urine of nephrotic patients [ll], quantitative 
measurements have not yet been done. We, therefore, compared serum lipoprotein 
patterns in patients with untreated nephrotic syndrome with the excretion of high 
density lipoproteins in urine. Quantitation of urinary HDL was performed by 
cholesterol measurements in HDL fractions after ultrafiltration and gel chromatog- 
raphy of the urinary samples. Although our results show a positive correlation 
between serum LDL-cholesterol and urinary HDL-cholesterol the amount of the 
daily urinary loss of HDL seems not to be sufficient to explain the hyperlipidemia 
in patients with nephrotic syndrome. 
Materials and methods 
Patients 
Nineteen patients (age 17 to 69 yr) with nephrotic syndrome of various origins 
were included in the study (Table I). Diagnoses were established by the laboratory 
finding of proteinuria (> 2 g/24 h) as well as renal sonography, intravenous 
urography, cystoscopy and ~stolo~cal examination of biopsies. Five patients 
suffered from diabetic nephropathy, 4 had perimembranous, 3 epimembranous, 2 
mesa&al proliferative, 1 membranous-proliferative and 1 proliferative glomerulo- 
nephritis. Two renal biopsies showed focal glomerulosclerosis and 1 minimal 
glomerular lesions. 
In each patient the 24 h-urine and blood specimens after fasting overnight were 
collected at the same time. No steroids were applied and no restrictive diets were 
kept during the collection period. 
Chemical assays 
Total serum albumin was measured with a Technicon SMA 12/60 Multiple 
Analyzer. Total serum cholesterol and triglyceride determinations were performed 
e~ymatically with commercial test kits (Boe~nger, Man~eim, FRG) [12,13]. 
Urinary protein was determined with the Biuret reagent [14]. Total cholesterol in 
urine was analyzed by gas-liquid chromatography using a Perkin Elmer chromato- 
graph (model 900) with flame ionization detectors and a 180 cm x 2 mm, 1% XE 60 
column, column temperature 220 o C, as described previously [15]. 
Se~aratian of serum ~~~ap~oteins 
Serum lipoproteins were separated at d = 1.006 g/ml by preparative ultracentri- 
fugation (105 000 x g, 22 h, 4’ C) [16]. VLDL was removed by slicing the tube. In 
the infranate, LDL and HDL were further separated by precipitation with sodium 
phosphotungstate and magnesium chloride [17]. 
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TABLE I 
Serum albumin and lipids in 19 nephrotic patients 
Patients Age Sex Serum Serum Serum VLDL- LDL- HDL- 
albumin choles- trigly- choles- choles- choles- 
(g/dJ) terol cerides terol terol terol 
(mg/dB (mg/dJ) (mg/dB (mg/dB (mg/dl) 
1. B.R. 69 f 3.7 197 261 45 135 26 
2. B.M. 34 m 3.5 249 253 71 186 36 
3. B.H. 59 m 2.6 464 570 103 183 38 
4. D.A. 55 m 3.0 316 88 25 230 37 
5. F.J. 47 m 1.8 693 630 152 418 40 
6. H.W. 50 m 2.6 284 234 61 163 29 
7. H.F. 42 m 3.7 284 326 69 218 21 
8. H.A. 40 m 4.1 232 213 41 144 56 
9. H.J. 69 f 4.0 245 349 61 150 21 
10. K.A. 39 m 2.7 403 242 68 306 30 
11. K.Z. 44 m 2.5 340 264 63 244 19 
12. L.S. 52 f 1.7 485 465 135 300 SO 
13. L.A. 22 m 4.7 221 137 33 141 33 
14. M.M. 21 f 3.3 191 153 28 130 32 
15. N.F. 62 m 2.4 422 327 75 331 38 
16. R.M. 37 m 3.2 209 143 21 151 37 
17. S.J. 50 m 3.2 197 253 37 154 23 
18. S.E. 69 f 3.0 198 161 19 191 19 
19. W.C. 17 f 2.1 543 113 44 443 64 
Range 1.7-4.7 191-693 88-630 19-152 130-443 19-64 
Median value 3.0 284 253 45 186 33 
Normal value 3.7-4.8 < 230 C200 <: 30 <I80 >m35/f40 
Isolation of urinal high density ~ip~Fr~te~ns 
Within 1 h after the collection the 24 h-urine samples were passed through a 
Selecta filter no. 1117 l/2 (Schleicher Schtill, Dassel, FRG) in order to remove 
cellular debris of 5 to 10 pm in diameter. Then, NaCl was added up to a final 
concentration of 0.56 mol/l to precipitate the Tamm-Horsefall mucoprotein [18], 
which was removed by centrifugation for 10 min at 8000 rpm. Before the super- 
natant (90% of the volume) was concentrated by ultraf~tration at 4°C to a final 
volume of 3 to 5 ml in a stirred cell (Amicon, Witten, FRG; models 402 and 52) 
with PM 10 membranes, 0.2 g sodium azide (NaN,) and 0.05 mm01 phenyl- 
methanesulfonyl fluoride (PMSF) in 100% isopropanol were added per 1000 ml of 
urine to avoid bacterial and enzymatic degradation. Aliquots of 2 to 3 ml of the 
concentrated urine were used for gel chromatography on a 100 x 2.5 cm Sephadex 
G-100 column. Elution was performed with 0.15 mol/l NaCl, 0.1 g/l Na,-EDTA, 
0.2 g/l NaN, and 0.05 mmol/l PMSF at pH 7.0 [19]. Usually 70 to 80 8-ml 
fractions were collected. The absorbance at 280 nm was recorded with a spectropho- 
tometer (Beckman, Fullerton, CA, model 24) and total cholesterol was measured by 
gas-liquid chromatography. The cholesterol containing fractions were pooled and 
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concentrated to 3 to 5 ml. After r~~omato~aphy on a 120 X 1.8 cm Siogel A 5 m 
column about 50 g-ml fractions were collected. The absorbance at 280 nm and the 
cholesterol concentrations were plotted graphically. The elution pattern revealed 2 
or 3 peaks, which were pooled and concentrated each to 0.5 to 2 ml. 
Recovery studies for cholesterol showed a total loss between 30 and 50% at the 
end of the fractionation. 
Immunodiffusion 
Ouchterlony immunodiffusion was performed in 15 g/l bactoagar (0.02 mol/l 
sodium diethylbarbiturate, 0.03 mol/l sodium acetate), pH 8.6. The glass plates 
were incubated for 48 h at 20 ’ C. The staining was done with azokarmine B (Sigma, 
Miinchen, FRG). We tested against antisera against q- and ~-~poproteins (Behr- 
ing, Marburg, FRG) identical to apoHDL and apoLDL, respectively. 
Statistical analysis 
Using ranges and median values the statistical analysis of our data was carried 
out applying the t-test, the Spearman rank correlation coefficient and the analysis of 
the regression line 1201. 
Results 
Serum albumin, lipids and lipoproteins 
Single values of serum albumin, total cholesterol, triglycerides, VLDL-, LDL- 
and HDL-cholesterol of 19 patients with nephrotic syndrome are listed in Table I. 
In 14 out of 19 serum samples hypoalbuminemia was found. Only 4 patients had 
normal serum cholesterol and triglyceride concentrations, one of which showed a 
regular cholesterol distribution on the three main, lipoprotein classes. In the remain- 
ing 18 patients at least one lipid parameter was abnormal. In 10 patients we found 
decreased plasma HDL-cholesterol levels and in 11 elevated plasma LDL-cholesterol 
concentrations. 
Urinary protein, total cholesterol and HDL-cholesterol 
The total urinary protein excretion varied from 2.0 to 24.5 g/24 h (median value 
4.9 g/24 h) and total urinary cholesterol concentrations from 3.1 mg to 68.7 mg/24 
h (median value 20.0 mg/24 h) (Table II). 
For isolation of urinary HDL lower molecular proteins were separated from 
urinary lipids by gel filtration on a Sephadex G-100 column. The cholesterol 
containing void volume fractions were pooled, concentrated and fractionated subse- 
quently on the Biogel A Sm. column. In 13 patients an elution profile with two main 
peaks was seen (Fig. la). The first peak represented urinary cholesterol associated 
with membrane proteolipids which have been characterized previously [15]. The 
second peak was identified as HDL by immunodiffusion. In the remaining 6 
patients the elution pattern revealed 3 peaks (Fig. lb). The middle peak did contain 
LDL in only one urine sample and contained larger HDL aggregates in the others. 
Single values of urinary HDL-cholesterol were given in Table II. 
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TABLE II 
Urinary protein, cholesterol and HDL-cholesterol excretion in nephrotic patients 
Patients 
1. B.R. 
2. B.M. 
3. B.H. 
4. D.A. 
5. F.J. 
6. H.W. 
I. H.F. 
8. H.A. 
9. H.J. 
10. K.A. 
11. K.Z. 
12. L.S. 
13. L.A. 
14. M.M. 
15. N.F. 
16. R.M. 
17. S.J. 
18. SE. 
19. W.C. 
Range 
Median value 
Protein Cholesterol HDL-cholesterol 
(g/24 h) (mg/24 h) (mg/24 h) 
3.2 19.8 2.9 
24.5 51.9 1.7 
7.0 20.0 1.0 
6.9 12.2 0.7 
3.3 10.2 4.1 
4.1 5.9 0.1 
3.0 4.5 0.7 
3.1 6.2 0.1 
2.5 6.4 0.3 
4.9 24.6 1.6 
5.1 9.8 3.1 
3.3 42.9 8.3 
8.2 68.7 0.2 
2.0 3.1 0.4 
21.0 42.8 5.0 
23.2 5.0 1.0 
18.3 38.0 1.4 
3.8 21.4 2.2 
7.7 21.5 0.9 
2.0-24.5 3.1-68.7 0.1-8.3 
4.9 20.0 1.0 
Serum-urine correlations 
According to the statistical analysis the urinary total protein correlated signifi- 
cantly with urinary total cholesterol (r = + 0.76, p < 0.01) (Fig. 2a). There was an 
b 
ELUTION VOLUME ML 
Fig. 1. a. Gel chromatographic elution pattern of a concentrated urinary sample on Biogel A 5m (two 
peaks). b. Gel chromatographic elution pattern of a concentrated urinary sample on Biogel A 5m (3 
peaks). Column sire 120 x 1.8 cm. Individual points represent total cholesterol concentrations (A -----A) 
and the absorbance at 280 nm (0 - 0) measured in each collected fraction. V,,, void volume. 
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inverse correlation between serum albumin and serum total cholesterol (r = - 0.78, 
p < 0.01) (Fig. 2b) and a positive correlation between urinary HDL-cholesterol and 
serum LDL-cholesterol (r = + 0.54, p < 0.05) (Fig. 2~). Urinary total protein and 
serum albumin (r = - 0.25), urinary total cholesterol and plasma total cholesterol 
(r = + O.Ol), urinary HDL-cholesterol and plasma HDL-cholesterol (r = +O.OE) 
l 
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Fig. 2. a. Correlation between urinary protein and urinary total cholesterol (r = +0.76, p < O.Ol), 
y = 0.29x + 1.58. b. Correlation between serum albumin and serum total cholesterol (r = - 0.78, p < O.Ol), 
y = -0.0045x +4,5. c. Correlation between urinary HDL-cholesterol and serum LDL-cholesterol (r = 
+ 0.54, p -c 0.05), y = 0.016x - 1. 
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Fig. 2 (continued). 
and plasma HDL-cholesterol and plasma LDL-cholesterol (I = + 0.48) did not 
correlate significantly. 
Discussion 
Abnormal serum lipid and lipoprotein patterns are commonly found in the 
nephrotic syndrome [1,3]. However, the etiology of hyperlipoproteinemia has not yet 
been clarified completely. 
Our data confirmed altered serum lipoprotein concentrations in 17 and hypoal- 
buminemia in 14 of the 19 patients. Normal plasma cholesterol and triglyceride 
levels and a regular cholesterol distribution on the 3 main lipoprotein classes were 
found in one 17-yr-old man with a mild form of nephrotic syndrome, which had 
been diagnosed only 3 mth ago, another patient showed a normal lipoprotein 
pattern. These findings are in variance with Chopra and coworkers [6], who reported 
normal serum lipoprotein profiles in 16 out of 33 patients. This discrepancy can be 
explained by the fact that in contrast to them only patients without steroid 
treatment were included in our study. Nine patients showed hyperlipoproteinemia 
phenotype IIb, 6 had phenotype IV and 2 phenotype IIa. The predominance of 
phenotype II and IV is confirmed by other investigators [3,6], although all pheno- 
type of hyperlipoproteinemias can occur in the nephrotic syndrome. The presence of 
renal failure, special diets, the degree of hypoalbuminemia, age, sex and general 
condition of the patients or the etiology of nephrosis could be responsible for this 
heterogeneity [1,3]. 
Only few studies exist which take the urinary lipid and protein excretion into 
account [8,11]. Using double immunodiffusion and lipoprotein-electrophoresis 
Kashyap et al found HDL in the urine of 9 nephrotic patients investigated. LDL 
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was detected in only two of these patients with the nephrotic syndrome [ll]. In otlr 
patients proteinuria up to 24.5 g/24 h and cholesteroluria up to 68.7 mg/24 h were 
observed. After gel filtration of the concentrated urinary samples, besides the 
membrane proteolipids, which were eluted in the void volume fractions, HDL was 
regularly identified in the lower molecular weight peak fractions. Lipid recovery 
studies in single urinary specimens showed a total loss of urinary cholesterol 
between 30 and 50%. Especially during the two ultrafiltration steps a considerable 
loss of lipids occurred most likely due to adherence of lipoproteins to the PM 10 
membrane or to direct passage of free cholesterol molecules as a consequence of 
delipidation. Filtration using the Selecta filter 1117 l/2 and gel chromatography did 
not remove more than 5% of total cholesterol. 
The lipid-protein correlations in our study were in good accordance to the 
results published by other authors [2,8,21,22]. Urinary total protein and urinary 
total cholesterol correlated positively (r = + 0.76, p < 0.01). There was a significant 
inverse correlation between albumin and total cholesterol in serum (r = -0.78, 
p -e 0.01). Apple et al reported similar results recently and suggested that albumin 
concentration and oncotic pressure might be closely related to the signal for 
enhanced hepatic production of ~~protein lipids (211. In discrepancy to Gherardi 
et al we found no reciprocal relation between serum HDL cholesterol and LDL- 
cholesterol [3], but a positive correlation (r = + 0.54, p < 0.05) between serum 
LDL-cholesterol and urinary HDL-cholesterol. It has been speculated that the 
selective increase in lipoprotein-cholesterol fractions other than HDL cholesterol 
may relate in part to loss of HDL in the urine of patients with nephrosis [9,10]. 
HDL serves as a flexible reservoir in plasma for the physiolo~cally important apo C 
II molecules. These are activators of the lipoprotein lipase and influence the 
clearance of circulating triglycerides. Although LDL-cholesterol in serum and 
HDL-cholesterol in urine correlated positively in our study, the causative relation- 
ship of these findings is questionable. Our results demonstrate no inverse correlation 
between ~DL-cholesterol in serum and urine. The absolute amount of HDL 
excreted in the 24 h urine is obviously too small to decrease the HDL concentra- 
tions in serum significantly. Therefore, our results are inconsistent with the hypothe- 
sis [23] that the urinary loss of HDL might relate to the hyperlipidemia of nephrotic 
syndrome. 
The skilful technical assistance of Ms. B. Ziindt is gratefully acknowledged. 
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